ConductScience.org, home
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
API referenceFor AI assistants

Trial · NCT01447446

Adverse events1,860

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 1,860

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2a + Ribavirin4352,312
otherAnaemiaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2b + Ribavirin141496
otherAnaemiaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin112292
otherAnaemiaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin4293
otherAnaemiaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin351821
otherAnaemiaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin4386
otherNeutropeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2a + Ribavirin2582,312
otherNeutropeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2b + Ribavirin64496
otherNeutropeniaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin35292
otherNeutropeniaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin2593
otherNeutropeniaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin84821
otherNeutropeniaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin2486
otherLeukopeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2a + Ribavirin1292,312
otherLeukopeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2b + Ribavirin47496
otherLeukopeniaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin8292
otherLeukopeniaBlood and lymphatic system disordersTriple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin693
otherLeukopeniaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin59821
otherLeukopeniaBlood and lymphatic system disordersTriple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin3186
otherThrombocytopeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2a + Ribavirin1382,312
otherThrombocytopeniaBlood and lymphatic system disordersDual Therapy: Peg-IFN Alfa-2b + Ribavirin26496

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01447446/events

API referenceFor AI assistants